Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 4
2010 5
2011 5
2012 5
2013 3
2014 3
2015 2
2016 3
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Evolution of raltegravir resistance during therapy.
Sichtig N, Sierra S, Kaiser R, Däumer M, Reuter S, Schülter E, Altmann A, Fätkenheuer G, Dittmer U, Pfister H, Esser S. Sichtig N, et al. Among authors: schulter e. J Antimicrob Chemother. 2009 Jul;64(1):25-32. doi: 10.1093/jac/dkp153. Epub 2009 May 14. J Antimicrob Chemother. 2009. PMID: 19447792
Proviral DNA as a Target for HIV-1 Resistance Analysis.
Lübke N, Di Cristanziano V, Sierra S, Knops E, Schülter E, Jensen B, Oette M, Lengauer T, Kaiser R. Lübke N, et al. Among authors: schulter e. Intervirology. 2015;58(3):184-9. doi: 10.1159/000431093. Epub 2015 Jun 27. Intervirology. 2015. PMID: 26139571 Free article.
Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey.
De Luca A, Pezzotti P, Boucher C, Döring M, Incardona F, Kaiser R, Lengauer T, Pfeifer N, Schülter E, Vandamme AM, Zazzi M, Geretti AM; EucoHIV Study Group. De Luca A, et al. Among authors: schulter e. PLoS One. 2019 Nov 21;14(11):e0225381. doi: 10.1371/journal.pone.0225381. eCollection 2019. PLoS One. 2019. PMID: 31751385 Free PMC article.
Time on drug analysis based on real life data.
Schülter E, Kaiser R, Zazzi M, Sönnerborg A, Camacho R, Verheyen J. Schülter E, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19790. doi: 10.7448/IAS.17.4.19790. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397534 Free PMC article.
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain. De Luca A, et al. J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11. J Infect Dis. 2013. PMID: 23315324
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, Torti C, Schülter E, Clotet B, Sönnerborg A, De Luca A, Grossman Z, Struck D, Vandamme AM, Abecasis AB. Theys K, et al. Among authors: schulter e. Antimicrob Agents Chemother. 2013 Feb;57(2):1053-6. doi: 10.1128/AAC.01668-12. Epub 2012 Nov 26. Antimicrob Agents Chemother. 2013. PMID: 23183438 Free PMC article.
29 results